Apolipoprotein
Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III. Specific apolipoproteins function in the regulation of lipoprotein metabolism through their involvement in the transport and redistribution of lipids among various cells and tissues, through their role as cofactors for enzymes of lipid metabolism, or through their maintenance of the structure of the lipoprotein particles.
Apolipoprotein Isoform Specific Products
All Product Categories
-
Apolipoprotein Related Products (86)
Related Products (86)
-
Apolipoprotein Isoform Comparison
-
5(Z),11(Z),14(Z)-Eicosatrienoic acid
0 Images5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
-
STT-5058
0 ImagesCat. No.: HY-P992470Synonyms: ARGX-116; NN5058STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases.
-
Opemalirsen
0 ImagesCat. No.: HY-177653CAS No.: 2639853-99-7Synonyms: AZD2373, ION-972190Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.
-
Lepodisiran sodium
0 ImagesCat. No.: HY-177640ACAS No.: 2766131-24-0Synonyms: LY3819469 sodiumLepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease.
-
Pirifibrate
0 ImagesCat. No.: HY-106581CAS No.: 55285-45-5Synonyms: EL-466Pirifibrate (EL-466) is a lipid-lowering compound. Pirifibrate slightly increases α-lipoprotein levels. Pirifibrate can be used for the research of type IIa, IIb and IV hyperlipoproteinemia.
-
Anti-ApoL1 Antibody
0 ImagesCat. No.: HY-P992191
-
Opemalirsen sodium scrambled negative control
0 ImagesCat. No.: HY-177653BOpemalirsen sodium scrambled negative control is the sequence scrambled negative control of Opemalirsen sodium.
-
MEDI-5884
0 ImagesCat. No.: HY-P991574CAS No.: 2643310-75-0Synonyms: REG-101MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.
-
PH-002-d8
0 ImagesCat. No.: HY-112798SPH-002-d8 is the deuterium labeled PH-002 (HY-112798). PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.
-
Lp(a)-IN-5 hydrochloride
0 ImagesLp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
-
Plozasiran sodium scrambled negative control
0 ImagesCat. No.: HY-164740BPlozasiran sodium scrambled negative control is the sequence scrambled negative control of Plozasiran sodium.
-
COG112
0 ImagesCat. No.: HY-P11502CAS No.: 1314623-74-9COG112 is an antennapedia-linked apoE-mimetic peptide. COG112 attenuates induction of NO production, inhibits CXC chemokines KC and MIP-2. COG112 reduces nuclear translocation of NF-κB. COG112 inhibits phosphorylation of IκB-α and prevents the degradation of IκB-α. COG112 inhibits the inflammatory response to Citrobacter rodentium .
-
Obicetrapib sodium
0 ImagesCat. No.: HY-18778ACAS No.: 866399-88-4Synonyms: TA-8995 sodium; DEZ-001 sodium; AMG-899 sodiumObicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
-
Lp(a)-IN-7
0 ImagesCat. No.: HY-173323CAS No.: 3070232-49-1Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC50 of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease.
-
4010B-30
0 ImagesCat. No.: HY-117555CAS No.: 1415477-76-74010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE-/- mice.
-
Olezarsen sodium scrambled negative control
0 ImagesCat. No.: HY-153491BOlezarsen sodium scrambled negative control is the sequence scrambled negative control of Olezarsen sodium.
-
Cy3 labled Zerlasiran sodium
0 ImagesCat. No.: HY-147425ESynonyms: Cy3 labled SLN360 sodiumCy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
-
apoB (4372-4392)
0 ImagesCat. No.: HY-P10188CAS No.: 255822-48-1apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.
-
Lp(a)-IN-5
0 ImagesCat. No.: HY-171464CAS No.: 2924841-79-0Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
-
1-Linoleoyl Glycerol (Standard)
0 ImagesCat. No.: HY-111346RCAS No.: 2277-28-3Synonyms: 1-Linoleoyl-rac-glycerol (Standard); 1-Monolinolein (Standard)1-Linoleoyl Glycerol (Standard) is the analytical standard of 1-Linoleoyl Glycerol. This product is intended for research and analytical applications. 1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
